IL6

IL6 Full Name

Interleukin 6

IL6 Introduction

Interleukin 6 is one of the most extensively studied inflammatory cytokines in molecular medicine because of its central role in immune regulation, tissue repair, and chronic inflammatory disease progression. Produced by immune cells such as macrophages, T cells, fibroblasts, and endothelial cells, IL6 acts as a multifunctional signaling molecule that helps the body respond to infection, injury, and environmental stress. However, persistent or dysregulated IL6 signaling can drive excessive inflammation, immune imbalance, and tissue damage, making it a major concern for researchers and clinicians seeking more effective therapeutic strategies. Increasing evidence from translational and clinical studies has positioned IL6 as both a biomarker and a therapeutic target in inflammatory disorders, cancer biology, and immune-mediated diseases, particularly because abnormal IL6 activity is closely associated with disease severity, progression, and treatment resistance.

From a functional perspective, IL6 is best known for activating the JAK/STAT3 signaling pathway after binding to the IL6 receptor complex, thereby regulating gene expression linked to immune activation, acute-phase responses, cell survival, and hematopoiesis. This signaling network plays a critical role in coordinating host defense mechanisms, but it can also contribute to pathological inflammation when chronically activated. Researchers have increasingly focused on IL6 because elevated circulating IL6 levels are commonly observed in patients suffering from autoimmune diseases, metabolic disorders, cardiovascular complications, and severe infections. In oncology research, IL6 has gained substantial attention for its ability to shape the tumor microenvironment, promote angiogenesis, support cancer stem cell survival, and enhance tumor immune evasion. Recent ovarian cancer studies further suggest that IL6 may influence whether tumors exhibit "hot" or "cold" immune characteristics, directly affecting patient prognosis and responsiveness to immunotherapy approaches.

The clinical importance of IL6 has led to the rapid development of targeted immunotherapies designed to block IL6 or its receptor signaling pathways. Therapeutic inhibition of IL6 has already shown value in diseases such as rheumatoid arthritis, cytokine release syndrome, and other systemic inflammatory conditions, while ongoing studies continue to evaluate its broader applications in oncology, fibrosis, neurodegeneration, and precision medicine. Because chronic inflammation is now recognized as a driving force behind many complex diseases, IL6 remains a high-priority molecular target for drug discovery and biomarker development. For researchers, biotech companies, and pharmaceutical developers, understanding IL6 biology is essential for designing next-generation anti-inflammatory therapies, improving diagnostic accuracy, and identifying predictive markers that can guide personalized treatment strategies in modern translational medicine.

Alternate Names for IL6

IL6; interleukin 6; HGF; HSF; BSF2; IL-6; IFNB2; interleukin-6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; interferon; beta 2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor; PF-04236921

• 1.Trovato M, et al.; Interleukin‑6 signalling as a valuable cornerstone for molecular medicine (Review). Int J Mol Med. 2021, 47(6):107.
  2.Tanaka T, et al.; Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018, 10(8):a028456.